Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial.

Jonas Sundén-CullbergPuran ChenHenrike HäbelPaul SkorupHelena JanolsJohan RasmusonKatarina NiwardÅse Östholm BalkhedKaterina ChatzidionysiouHilmir AsgeirssonOla BlennowÅsa ParkeAnna-Karin SvenssonJagadeeswara Rao MuvvaHans-Gustav Ljunggrennull nullAnna-Carin HorneUlrika ÅdénJan-Inge HenterAnders SönnerborgJan VesterbackaPiotr NowakJon Lampa

Published in: PloS one (2023)

Premature closure of trial precludes firm conclusions. Anakinra or tocilizumab did not significantly shorten time to clinical recovery compared to usual care. (IMMCoVA, NCT04412291, EudraCT: 2020-00174824).

Keyphrases

phase iii
open label
phase ii
study protocol
rheumatoid arthritis
clinical trial
healthcare
coronavirus disease
juvenile idiopathic arthritis
rheumatoid arthritis patients
sars cov
palliative care
early onset
phase ii study
pain management
adverse drug
placebo controlled
locally advanced